← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Cabometyx

nivolumab with cabozantinib · Bristol Myers Squibb / Exelixis

FDA approvalNew or expanded indicationRenal cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line therapy for patients with advanced renal cell carcinoma.

LAMPGEN ANALYSIS

Why it matters

The decision pairs immune checkpoint blockade with a multikinase inhibitor in the first-line setting.

What research teams should watch

Track oral cabozantinib adherence and infusion timing together, with attribution procedures for overlapping toxicities.

PRIMARY RECORDS

Sources